NasdaqCM - Nasdaq Real Time Price • USD Sonoma Pharmaceuticals, Inc. (SNOA) Follow Compare 2.5800 -0.0700 (-2.64%) At close: January 13 at 4:00:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and ... Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag Sonoma Pharmaceuticals ( NASDAQ:SNOA ) Second Quarter 2025 Results Key Financial Results Revenue: US$3.58m (up 31% from... Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results Revenue increased 31% for the quarter compared to same period prior year Positive cash flows from operations of $0.35 million for the quarter Net loss improved 59% for the quarter compared to same period prior year Net loss per share improved 90% ... Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf BOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences BOULDER, CO / ACCESSWIRE / October 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule BOULDER, CO / ACCESSWIRE / September 19, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution BOULDER, CO / ACCESSWIRE / September 17, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line BOULDER, CO / ACCESSWIRE / September 11, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock BOULDER, CO / ACCESSWIRE / August 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff BOULDER, CO / ACCESSWIRE / August 26, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States BOULDER, CO / ACCESSWIRE / August 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations Sonoma Pharmaceuticals ( NASDAQ:SNOA ) First Quarter 2025 Results Key Financial Results Revenue: US$3.39m (down 1.1... Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results European revenues increased 20% compared to same period last year Gross margin of 39% compared to 35% in same period last year Net loss improved 19% compared to same period last year BOULDER, CO / ACCESSWIRE / August 8, 2024 / Sonoma Pharmaceuticals, ... Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum Sonoma Pharmaceuticals (SNOA) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices. Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine BOULDER, CO / ACCESSWIRE / July 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... Sonoma Pharmaceuticals (SNOA) Shows Fast-paced Momentum But Is Still a Bargain Stock If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. Performance Overview Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 Return SNOA S&P 500 YTD -6.18% -1.20% 1-Year -28.33% +22.00% 3-Year -97.25% +23.48%